A9481
AD 198
≥98% (HPLC), solid
Synonym(s):
N-Benzyladriamycin-14-valerate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C39H43NO12
CAS Number:
Molecular Weight:
717.76
UNSPSC Code:
12352200
assay
≥98% (HPLC)
form
solid
color
red
solubility
DMSO: >10 mg/mL, H2O: insoluble
storage temp.
2-8°C
SMILES string
CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NCc3ccccc3)[C@H](O)[C@H](C)O2)c4c(O)c5C(=O)c6c(OC)cccc6C(=O)c5c(O)c4C1
Biochem/physiol Actions
AD 198 is a PKC-delta activator. Phospholipid scramblase 3 (PLS3) is an enzyme that plays a critical role in mitochondrial morphology, functions, and apoptotic response. During apoptosis, activated protein kinase C-delta (PKC-delta) translocates to mitochondria and phosphorylates PLS3. Used to show that PLS3 is a critical downstream effector of PKC-delta in AD 198-induced apoptosis.
AD 198 is a PKC-delta activator.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yongwen He et al.
Cancer research, 65(21), 10016-10023 (2005-11-04)
Phospholipid scramblase 3 (PLS3) is an enzyme that plays a critical role in mitochondrial morphology, functions, and apoptotic response. During apoptosis, activated protein kinase C-delta (PKC-delta) translocates to mitochondria and phosphorylates PLS3. Here, we utilize an extranuclear-targeted anthracycline N-benzyladriamycin-14-valerate (AD198)
K Kashfi et al.
Biochemical pharmacology, 40(7), 1441-1448 (1990-10-01)
Adriamycin (ADR; doxorubicin) and its highly lipophilic, less toxic analogue N-benzyl-adriamycin-14-valerate (AD 198) were found to inhibit rat heart and liver carnitine palmitoyltransferases of both mitochondrial outer and inner membranes. The outer membrane enzyme was more sensitive to inhibition by
Leonard Lothstein et al.
Leukemia research, 31(8), 1085-1095 (2006-12-26)
Bcr-Abl activity in chronic myelogenous leukemia (CML) results in dysregulated cell proliferation and resistance against multiple cytotoxic agents due to the constitutive activation of proliferative signaling pathways. Currently, the most effective treatment of CML is the inhibition of Bcr-Abl activity
L Lothstein et al.
Oncology research, 4(8-9), 341-347 (1992-01-01)
N-Benzyladriamycin-14-valerate (AD 198) is a highly hydrophobic analogue of Adriamycin (ADR) which can circumvent multidrug resistance (MDR) in various cell lines. Unlike ADR, AD 198 avoids extrusion by P-glycoprotein (P-gp) in AD 198-resistant murine macrophage-like J774.2 cells and localizes in
R Ganapathi et al.
British journal of cancer, 60(6), 819-826 (1989-12-01)
N-Benzyladriamycin-14-valerate (AD198) is a novel lipophilic anthracycline with greater in vivo antitumour activity than doxorubicin (DOX) in experimental model systems. Using sensitive and progressively DOX-resistant L1210 mouse leukaemia and B16-BL6 mouse melanoma lines, we have determined the cellular pharmacokinetics and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service